Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ascrinvacumab, panulisib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 5542
Sealed predictions
- ACVRL1 in dopamine neurons, braak-0.05 (p 0.893) → -0.33 (p 0.393)receipt 5550
Swarm cases
receipt 5550: ACVRL1 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.735, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.861, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.239, n 18). could be the mix.
- skeptic
- leave-one-out range -0.25 to +0.00, sign flips 3; without severely affected donors -0.09 (p 0.735, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACVRL1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts